1-alpha,25-dihydroxyvitamin D3 regresses endometriotic implants in rats by inhibiting neovascularization and altering regulation of matrix metalloproteinase

Postgraduate Medicine

Volumn 126, Issue 1, 2014, Pages 104-110

  Yildirim, Basak ^a   Guler, Tolga ^a   Akbulut, Metin ^b   Oztekin, Ozer ^a   Sariiz, Gulcin ^a  

^a Department of Obstetrics and Gynecology ^*  (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

1 alpha; 25 dihydroxyvitamin D3; Endometriosis; Metalloproteinase 9; Tissue inhibitor of metalloproteinase 2; Vascular endothelial growth factor

Indexed keywords

CALCITRIOL; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; 1 ALPHA, 25 DIFLUOROVITAMIN D3; 1-ALPHA, 25-DIFLUOROVITAMIN D3; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; VASCULOTROPIN A; VITAMIN D;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOMETRIOSIS; FEMALE; HISTOPATHOLOGY; IMMUNOREACTIVITY; LAPAROTOMY; NONHUMAN; PERITONEAL CAVITY; RAT; REMISSION; TISSUE IMPLANT; UTERINE TISSUE; ANIMAL; DISEASE MODEL; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); ORGAN SIZE; PATHOPHYSIOLOGY; WISTAR RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; FEMALE; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SIZE; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN D;

EID: 84897018482     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.01.2730     Document Type: Article

References (29)

1. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–1799.
2. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535–549.
3. Osuga Y. Current concepts of the pathogenesis of endometriosis. Reprod Med Biol. 2010;9:1–7.
4. Salamonsen LA, Woolley DE. Matrix metalloproteinases in normal menstruation. Hum Reprod. 1996;11(Suppl 2):124–133.
5. Osteen KG, Yeaman GR, Bruner-Tran KL. Matrix metalloproteinases and endometriosis. Semin Reprod Med. 2003;21(2):155–164.
6. Collette T, Bellehumeur C, Kats R, et al. Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod. 2004;19(6):1257–1264.
7. Huang HF, Hong LH, Tan Y, Sheng JZ. Matrix metalloproteinase 2 is associated with changes in steroid hormones in the sera and peritoneal fluid of patients with endometriosis. Fertil Steril. 2004;81(5):1235–1239.
8. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74(2):111–122.
9. Chung HW, Lee JY, Moon HS, et al. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril. 2002;78(4):787–795.
10. Uzan C, Cortez A, Dufournet C, Fauvet R, Siffroi JP, Daraï E. Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases-2, -3 and -11, and of tissue inhibitor metalloproteinases-1 and -2. Virchows Arch. 2004;445(6):603–609.
11. Vanoirbeek E, Krishnan A, Eelen G, et al. The anti-cancer and antiinflammatory actions of 1,25(OH)2D3. Best Pract Res Clin Endocrinol Metab. 2011;25(4):593–604.
12. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000;87(3):214–220.
13. Agic A, Xu H, Altgassen C, et al. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci. 2007;14(5):486–497.
14. Chung I, Han G, Seshadri M, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009;69(3):967–975.
15. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007;6(4):1433–1439.
16. Mariani M, Viganò P, Gentilini D, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012;27(7):2010–2019.
17. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5):684–694.
18. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004;82(Suppl 3):1008–1013.
19. Güney M, Oral B, Karahan N, Mungan T. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril. 2008;89(4):934–942.
20. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–721.
21. Taylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011;18(9):814–823.
22. Nasu K, Yuge A, Tsuno A, Narahara H. Simvastatin inhibits the proliferation and the contractility of human endometriotic stromal cells: a promising agent for the treatment of endometriosis. Fertil Steril. 2009;92(6):2097–2099.
23. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10(4):482–496.
24. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol. 2010;321(2):103–111.
25. Osuga Y, Koga K, Hirota Y, Hirata T, Yoshino O, Taketani Y. Lymphocytes in endometriosis. Am J Reprod Immunol. 2011;65(1):1–10.
26. Ferrero S, Gillott DJ, Anserini P, et al. Vitamin D binding protein in endometriosis. J Soc Gynecol Investig. 2005;12(4):272–277.
27. Somigliana E, Panina-Bordignon P, Murone S, Di Lucia P, Vercellini P, Vigano P. Vitamin D reserve is higher in women with endometriosis. Hum Reprod. 2007;22(8):2273–2278.
28. Vilarino FL, Bianco B, Lerner TG, et al. Analysis of vitamin D receptor gene polymorphisms in women with and without endometriosis. Hum Immunol. 2011;72(4):359–363.
29. Abbas MA, Taha MO, Disi AM, Shomaf M. Regression of endometrial implants treated with vitamin D3 in a rat model of endometriosis. Eur J Pharmacol. 2013;715(1-3):72–75.